Gyre Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
Gyre Therapeutics, Inc. (GYRE) had Lessee, Operating Lease, Liability, to be Paid, Year One of $1.12 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-08-07
- 2026-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $1.12M.
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $307.00K.
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $668.00K.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $661.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2026-06-30 | $1.12M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $307.00K 10-Q · filed 2026-05-08 |
| 2025-12-31 | $668.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $661.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $657.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $279.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $782.00K 10-K · filed 2025-03-17 |
| 2024-09-30 | $766.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $735.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $103.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $226.00K 10-K · filed 2024-03-27 |
| 2022-12-31 | $38.00K 10-K · filed 2023-03-30 |
| 2022-09-30 | $195.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $410.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $410.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $2.04M 10-K · filed 2022-03-31 |
| 2021-09-30 | $1.72M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $1.72M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $762.00K 10-Q · filed 2021-05-06 |
| 2020-12-31 | $739.00K 10-K · filed 2021-03-04 |
| 2020-09-30 | $596.00K 10-Q · filed 2020-11-05 |
| 2019-12-31 | $578.00K 10-K · filed 2020-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |